UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of hepatocellular carcinoma in the time of COVID-19

Annals of oncology, 2020-08, Vol.31 (8), p.1084-1085

2020

Volltextzugriff (PDF)

First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice

Journal of viral hepatitis, 2012-06, Vol.19 (6), p.377-386

2012

Volltextzugriff (PDF)

Review article: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients

Alimentary pharmacology & therapeutics, 2016-07, Vol.44 (1), p.16-34

2016

Volltextzugriff (PDF)

Editorial: good news to patients with thalassaemia—HCV clearance made easy with direct‐acting antivirals

Alimentary pharmacology & therapeutics, 2017-09, Vol.46 (6), p.628-629

2017

Volltextzugriff (PDF)

Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19”

Journal of hepatology, 2020-12, Vol.73 (6), p.1570-1571

2020

Volltextzugriff (PDF)

Systematic review with meta‐analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon‐therapy in hepatitis B infection?

Alimentary pharmacology & therapeutics, 2014-03, Vol.39 (6), p.569-578

2014

Volltextzugriff (PDF)

Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection

Alimentary pharmacology & therapeutics, 2016-10, Vol.44 (7), p.653-661

2016

Volltextzugriff (PDF)

Preprocedural prophylaxis with blood products in patients with cirrhosis: Results from a survey of the Italian Association for the Study of the Liver (AISF)

Digestive and liver disease, 2022-11, Vol.54 (11), p.1520-1526

2022

Volltextzugriff (PDF)

Letter: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients – authors’ reply

Alimentary pharmacology & therapeutics, 2016-09, Vol.44 (5), p.538-538

2016

Volltextzugriff (PDF)

A baseline tool for predicting response to peginterferon alfa‐2a in HBeAg‐positive patients with chronic hepatitis B

Alimentary pharmacology & therapeutics, 2018-09, Vol.48 (5), p.547-555

2018

Volltextzugriff (PDF)

Prophylaxis and treatment of hepatitis B in immunocompromised patients

Digestive and liver disease, 2007-05, Vol.39 (5), p.397-408

2007

Volltextzugriff (PDF)

High efficacy of direct‐acting anti‐viral agents in hepatitis C virus‐infected cirrhotic patients with successfully treated hepatocellular carcinoma

Alimentary pharmacology & therapeutics, 2018-06, Vol.47 (12), p.1705-1712

2018

Volltextzugriff (PDF)

Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks?

Alimentary pharmacology & therapeutics, 2014-03, Vol.39 (5), p.548-549

2014

Volltextzugriff (PDF)

Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis

DIGESTIVE AND LIVER DISEASE, 2023-03, Vol.55, p.S73-S73

2023

Volltextzugriff (PDF)

Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data

DIGESTIVE AND LIVER DISEASE, 2023-03, Vol.55, p.S74-S74

2023

Volltextzugriff (PDF)

Dual cut‐off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation

Alimentary pharmacology & therapeutics, 2011-08, Vol.34 (3), p.353-362

2011

Volltextzugriff (PDF)

Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks

DIGESTIVE AND LIVER DISEASE, 2023-03, Vol.55, p.S72-S73

2023

Volltextzugriff (PDF)

A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B

Alimentary pharmacology & therapeutics, 2018-09, Vol.48 (5), p.564-573

2018

Volltextzugriff (PDF)

Commentary: absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C

Alimentary pharmacology & therapeutics, 2013-09, Vol.38 (5), p.553-554

2013

Volltextzugriff (PDF)

Long-Term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy

Hepatology (Baltimore, Md.), 2003-04, Vol.37 (4), p.756-763

2003

Volltextzugriff (PDF)

Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long‐term analogue therapy for hepatitis B

Alimentary pharmacology & therapeutics, 2018-08, Vol.48 (4), p.431-439

2018

Volltextzugriff (PDF)

An Easy-to-Use Baseline Score to Predict Response to Peginterferon Alfa-2a in Patients with Chronic Hepatitis B in Resource-Limited Settings

Journal of hepatology, 2016, Vol.64 (2), p.S600-S600

2016

Volltextzugriff (PDF)

High rates of renal tubular damage in HBV monoinfected patients long-term treated with Tenofovir: a cross-sectional, single center, real-life study in 414 patients

Journal of hepatology, 2017, Vol.66 (1), p.S689-S689

2017

Volltextzugriff (PDF)

Genetic variations in PD-1 and STAT4 genes do not predict off-treatment functional cure in IFN treated genotype D, HBeAg-negative patients with chronic hepatitis B

Journal of hepatology, 2017, Vol.66 (1), p.S261-S261

2017

Volltextzugriff (PDF)

Minimal increases of alpha-fetoprotein above the normal value strongly predict HCC development in compensated Caucasian HBV cirrhotics treated by entecavir or tenofovir: a 7-year longitudinal cohort study in 225 patients

Journal of hepatology, 2017, Vol.66 (1), p.S689-S690

2017

Volltextzugriff (PDF)

1 – 25 von 537

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(502)
Mit Volltextzugriff
(451)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Management of hepatocellular carcinoma in the time of COVID-19

First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice

Review article: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients

Editorial: good news to patients with thalassaemia—HCV clearance made easy with direct‐acting antivirals

Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19”

Systematic review with meta‐analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon‐therapy in hepatitis B infection?

Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection

Preprocedural prophylaxis with blood products in patients with cirrhosis: Results from a survey of the Italian Association for the Study of the Liver (AISF)

Letter: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients – authors’ reply

A baseline tool for predicting response to peginterferon alfa‐2a in HBeAg‐positive patients with chronic hepatitis B

Prophylaxis and treatment of hepatitis B in immunocompromised patients

High efficacy of direct‐acting anti‐viral agents in hepatitis C virus‐infected cirrhotic patients with successfully treated hepatocellular carcinoma

Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks?

Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis

Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data

Dual cut‐off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation

Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks

A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B

Commentary: absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C

Long-Term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy

Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long‐term analogue therapy for hepatitis B

An Easy-to-Use Baseline Score to Predict Response to Peginterferon Alfa-2a in Patients with Chronic Hepatitis B in Resource-Limited Settings

High rates of renal tubular damage in HBV monoinfected patients long-term treated with Tenofovir: a cross-sectional, single center, real-life study in 414 patients

Genetic variations in PD-1 and STAT4 genes do not predict off-treatment functional cure in IFN treated genotype D, HBeAg-negative patients with chronic hepatitis B

Minimal increases of alpha-fetoprotein above the normal value strongly predict HCC development in compensated Caucasian HBV cirrhotics treated by entecavir or tenofovir: a 7-year longitudinal cohort study in 225 patients

Suchergebnisse filtern